{
    "id": 28320,
    "fullName": "EGFR L792H",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR L792H lies within the protein kinase domain in the Egfr protein (UniProt.org). L792H has been demonstrated to occur as a secondary drug resistance mutation (PMID: 28093244, PMID: 28625641), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 11554,
                    "pubMedId": 28625641,
                    "title": "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28625641"
                },
                {
                    "id": 11553,
                    "pubMedId": 28093244,
                    "title": "Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in\u00a0Advanced NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28093244"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "L792H",
    "createDate": "06/26/2018",
    "updateDate": "10/06/2019",
    "referenceTranscriptCoordinates": {
        "id": 176079,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181384T>A",
        "cDna": "c.2375T>A",
        "protein": "p.L792H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14230,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29958,
                "profileName": "EGFR L792H EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14296,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R demonstrated some efficacy to treatment with Iressa (gefitinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29958,
                "profileName": "EGFR L792H EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14229,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29958,
                "profileName": "EGFR L792H EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14231,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Alunbrig (brigatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29958,
                "profileName": "EGFR L792H EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15777,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L792H EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15778,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) did not inhibit Egfr phosphorylation and proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L792H EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15794,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Tagrisso (osimertinib) and Erbitux (cetuximab) improved growth inhibition of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture compared to Tagrisso (osimertinib) alone (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L792H EGFR L858R"
            },
            "therapy": {
                "id": 7737,
                "therapyName": "Cetuximab + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15786,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L792H EGFR L858R"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15776,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L792H EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15790,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L792H EGFR L858R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15792,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L792H EGFR L858R"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15796,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, EGFR L792H was identified in 1.76% (6/340) of lung adenocarcinoma patients receiving Tagrisso (osimertinib), and 5 of the 6 patients also had EGFR T790M in cis, consistent with cell culture study and structural modeling that supports a role of EGFR L792H in cis with T790M in conferring resistance to Tagrisso (osimertinib) (PMID: 29857056).",
            "molecularProfile": {
                "id": 31220,
                "profileName": "EGFR T790M EGFR L792H"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20737,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, EGFR L792H with a coexisting EGFR T790M were identified in 2 of 100 patients with non-small cell lung cancer at treatment discontinuation of Tagrisso (osimertinib) (PMID: 31839416).",
            "molecularProfile": {
                "id": 31220,
                "profileName": "EGFR T790M EGFR L792H"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18023,
                    "pubMedId": 31839416,
                    "title": "Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31839416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29957,
            "profileName": "EGFR L792H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29958,
            "profileName": "EGFR L792H EGFR C797S EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31213,
            "profileName": "EGFR T790M EGFR L792H EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31220,
            "profileName": "EGFR T790M EGFR L792H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 176079,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181384T>A",
            "cDna": "c.2375T>A",
            "protein": "p.L792H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}